MDGL

Business Context and Reporting Period

Company: Madrigal Pharmaceuticals, Inc. (MDGL)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024

Madrigal is a biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH). In March 2024, the FDA granted accelerated approval for Rezdiffra (resmetirom), the first and only therapy approved for adults with noncirrhotic MASH with moderate to advanced liver fibrosis. Commercial sales began in April 2024. The company operates as a single reporting segment and is transitioning from a clinical-stage to a commercial-stage entity.

Key Financial Metrics

Liquidity: As of December 31, 2024, the company held approximately $931.3 million in cash, cash equivalents, and marketable securities. The company has an accumulated deficit of $1.8 billion.

Material Changes vs. Prior Period

• Revenue Generation: The company recorded $180.1 million in net product revenue in 2024, compared to zero in 2023, following the April 2024 commercial launch of Rezdiffra.
• SG&A Expenses: Selling, general, and administrative expenses surged 302% to $435.1 million, driven by the establishment of a commercial organization, marketing activities, and increased headcount.
• R&D Expenses: Research and development expenses decreased 13% to $236.7 million. This reduction was primarily due to lower clinical trial costs and a change in accounting where manufacturing costs were capitalized as inventory post-FDA approval rather than expensed.
• Capital Raise: In March 2024, the company completed an underwritten public offering raising approximately $659.9 million in net proceeds to fund commercialization and operations.

Guidance, Outlook, and Risks

Outlook and Strategy:

• Full Approval: Rezdiffra was approved via the accelerated pathway. Full approval is contingent on positive results from ongoing confirmatory outcomes trials (MAESTRO-NASH and MAESTRO-NASH OUTCOMES), with data expected in 2027.
• European Expansion: A Marketing Authorization Application (MAA) is under evaluation by the European Medicines Agency (EMA). A decision is expected in mid-2025, with a potential launch in Germany in the second half of 2025.
• Profitability: The company expects to continue incurring operating losses as it scales commercial operations and fulfills post-marketing commitments.

Key Risks and Contingencies:

• Accelerated Approval Risk: Failure to verify clinical benefit in post-marketing trials could result in withdrawal of approval.
• Reimbursement: Commercial success depends on third-party payer coverage and reimbursement rates, which remain uncertain.
• Competition: Over 150 drugs are in development for MASH, including competitors from large pharmaceutical companies expected to file for approval in 2025.
• Debt Covenants: The company has a $250 million loan facility with Hercules Capital. It must maintain minimum cash balances and may be subject to revenue covenants, though waivers apply if market capitalization exceeds $1.2 billion.

Investor Verification Checklist

• Revenue Quality: Verify the composition of the $180.1 million revenue, specifically the magnitude of "gross-to-net" adjustments (rebates, chargebacks, co-pay assistance) which totaled approximately $43.2 million in provisions.
• Customer Concentration: Confirm reliance on a limited number of specialty pharmacies; four customers accounted for 86% of gross revenue in 2024.
• Debt Status: Review compliance with the Hercules Capital loan covenants, specifically the minimum cash covenant and potential revenue triggers.
• Patent Expiry: Note that the composition-of-matter patent licensed from Roche expires in 2026, while other patents extend to 2033-2044.
• Cash Burn: Assess the runway provided by the $931 million cash balance against the projected increase in commercial and R&D spending.